natgillin/translations-raw huggingface dataset:
Most of these were mild or moderate upper respiratory tract infections such as nasopharyngitis and did not require treatment discontinuation. 
Večinoma je šlo za blage ali zmerne okužbe zgornjih dihal, kot je nazofaringitis, in zaradi njih ni bilo treba prekiniti zdravljenja.
Patients were blinded to the treatment regimen up to week 52, and the study continued to week 156. 
Bolniki do 52. tedna niso vedeli, kateri režim zdravljenja prejemajo (slepo zdravljenje), študija pa je za njih trajala 156 tednov.
** p values versus placebo and adjusted for multiplicity: p<0.0001. 
** vrednost p v primerjavi s placebom, prilagojena na številčnost primerjav: p<0,0001.
If possible, areas of the skin that show psoriasis should be avoided as injection sites. 
Če je mogoče, se je treba pri izbiri mesta za injiciranje izogniti predelom kože, ki so prizadeti zaradi psoriaze.
Improvements in the PASI 75 response were seen in both subgroups and the 300 mg dose showed statistically significant benefit in the anti-TNFα-IR patients. 
Izboljšanje pri doseganju odziva PASI 75 so opažali v obeh podskupinah, do statistično značilne prednosti pa je prišlo pri uporabi odmerka 300 mg pri anti-TNFα neodzivnih bolnikih.
• runny nose (rhinorrhoea) 
• izcedek iz nosu (rinoreja).
• cold sores (oral herpes) 
• herpes (oralni herpes),
After proper training in subcutaneous injection technique, patients may self-inject Cosentyx if a physician determines that this is appropriate. 
Ko se bolniki naučijo tehnike subkutanega injiciranja, si lahko zdravilo Cosentyx injicirajo sami, če zdravnik presodi, da je to primerno, in bolnikom zagotovi ustrezne kontrolne preglede.
A new and unused Cosentyx SensoReady pen (2 pens are needed for a 300 mg dose). 
nov in neuporabljen injekcijski peresnik SensoReady z zdravilom Cosentyx (za odmerek 300 mg potrebujete 2 injekcijska peresnika).
If a patient develops a serious infection, the patient should be closely monitored and secukinumab should not be administered until the infection resolves. 
Če pride do resne okužbe, je treba bolnika skrbno spremljati in prekiniti odmerjanje sekukinumaba, dokler okužba ni odpravljena.
• It is preferable to avoid the use of Cosentyx in pregnancy. 
• Najbolje je, da v času nosečnosti ne uporabljate zdravila Cosentyx.
Radiographs of hands, wrists, and feet were obtained at baseline, week 16 and/or week 24 and scored independently by at least two readers who were blinded to treatment group and visit number. 
Rentgenske posnetke rok, zapestij in stopal so pridobili ob izhodišču, v tednu 16 in/ali tednu 24, ocenila pa sta jih neodvisno najmanj dva ocenjevalca, in sicer slepo, brez dostopa do podatkov o zdravljeni skupini in zaporedni številki obiska.
In an additional psoriasis study (CLEAR) 676 patients were evaluated. 
V dodatni študiji psoriaze (študiji CLEAR) so ocenjevali 676 bolnikov.
If you forget to use Cosentyx 
Če ste pozabili uporabiti zdravilo Cosentyx
Treatment success of “clear” or “almost clear” consisted of no signs of psoriasis or normal to pink colouration of lesions, no thickening of the plaque and none to minimal focal scaling. 
Uspeh zdravljenja, ki je ocenjen z ocenama "brez znakov" oziroma "skoraj brez znakov", pomeni, da na koži ni nobenih znakov psoriaze oziroma da so lezije normalne do rožnate barve, brez zadebelitev v plake in brez luščenja ali z minimalnim luščenjem na posameznih mestih.
What Cosentyx is and what it is used for What you need to know before you use Cosentyx How to use Cosentyx 
Kaj je zdravilo Cosentyx in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Cosentyx Kako uporabljati zdravilo Cosentyx Možni neželeni učinki
Caution should be exercised when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection. 
Pri odločanju za uporabo sekukinumaba pri bolnikih s kronično okužbo ali z anamnezo ponavljajoče se okužbe je potrebna previdnost.
ACR: American College of Rheumatology; PASI: Psoriasis Area and Severity Index; DAS: Disease Activity Score; BSA: Body Surface Area 
ACR: po kriterijih Ameriške akademije za revmatologijo (ACR - American College of Rheumatology); PASI: indeks izraženosti psoriaze in velikosti prizadete površine kože (PASI - Psoriasis Area and Severity Index); DAS: ocena aktivnosti bolezni (DAS - Disease Activity Score)
Make sure you discuss with your doctor when you will have your injections and your follow-up appointments. 
Poskrbite, da se boste z zdravnikom dogovorili, kdaj boste prejemali injekcije in kdaj morate prihajati na kontrolne preglede.
You and your doctor should decide if you should inject Cosentyx yourself. 
Skupaj z zdravnikom se lahko odločita, da si boste zdravilo Cosentyx injicirali sami.
Do not inject into areas where the skin is tender, bruised, red, scaly or hard. 
Zdravila ne injicirajte v predele, kjer je koža bolj občutljiva, podpluta, rdeča, luskasta ali trda.
Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. 
Sekukinumab v klinično pomembni koncentraciji doseže kožo in zmanjša koncentracijo lokalnih označevalcev vnetja.
Bring the vial of powder to room temperature and ensure that the sterile water for injections is at room temperature. 
Pustite, da se viala s praškom ogreje na sobno temperaturo, in poskrbite, da bo tudi sterilna voda za injekcije sobne temperature.
Improvement in both endpoints was sustained for secukinumab patients who continued treatment through to week 24. 
Pri obeh ciljih študije je pri bolnikih, ki so prejemali sekukinumab in nadaljevali z zdravljenjem, izboljšanje vztrajalo do 24. tedna.
Instructions for reconstitution of Cosentyx 150 mg powder for solution for injection: Bring the vial of powder to room temperature and ensure that the sterile water for injections is at room temperature. 
Navodila za rekonstitucijo zdravila Cosentyx 150 mg prašek za raztopino za injiciranje: Pustite, da se viala s praškom ogreje na sobno temperaturo, in poskrbite, da bo tudi sterilna voda za injekcije sobne temperature.
Secukinumab is a monoclonal antibody which belongs to a group of medicines called interleukin (IL) inhibitors. 
Sekukinumab je monoklonsko protitelo in sodi v skupino zdravil, ki jih imenujemo zaviralci interlevkina (IL).
Replace the attached needle with a 27G x ½″ needle. 
Nameščeno iglo zamenjajte z iglo 27G x ½″ (12,7 mm).
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1). 
Zdravilo Cosentyx je kot samostojno zdravilo ali v kombinaciji z metotreksatom indicirano za zdravljenje aktivnega psoriatičnega artritisa pri odraslih bolnikih z nezadostnim odzivom na predhodno zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili (DMARD - Disease Modifying Anti-Rheumatic Drugs) (glejte poglavje 5.1).
Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). 
Sekukinumab je popolnoma humano monoklonsko protitelo IgG/κ, ki se selektivno veže na provnetni citokin interlevkin-17A (IL-17A) in ga nevtralizira.
Caution should be exercised when considering concomitant use of other immunosuppressants and secukinumab (see also section 4.5). 
Pri odločanju za sočasno uporabo drugih imunosupresivnih zdravil in sekukinumaba je potrebna previdnost (glejte tudi poglavje 4.5).
• severe itching of the skin, with a red rash or raised bumps. 
• hudo srbenje kože z rdečim izpuščajem ali bulicami.
Carefully withdraw slightly more than 1.0 ml of the solution for subcutaneous injection from the vial into a 1 ml graduated disposable syringe using a suitable needle (e.g. 21G x 2″). 
Iz viale v 1-mililitrsko brizgo z merilnimi oznakami za enkratno uporabo previdno potegnite nekoliko več kot 1,0 ml raztopine za subkutano injiciranje s pomočjo ustrezne igle (na primer igle 21G x 2 ″).
If you have received more Cosentyx than you should or the dose has been administered sooner than according to your doctor's prescription, inform your doctor. 
Če ste uporabili večji odmerek zdravila Cosentyx, kot bi smeli Če se prejeli več zdravila Cosentyx, kot bi smeli, ali ste odmerek prejeli prezgodaj glede na to, kar vam je predpisal zdravnik, obvestite zdravnika.
Patients randomised to etanercept received 50 mg doses twice per week for 12 weeks followed by 50 mg every week. 
Bolniki, ki so bili randomizirani na prejemanje etanercepta, so prejemali odmerek 50 mg dvakrat na teden 12 tednov, nato pa odmerek 50 mg enkrat na teden.
In clinical studies, infections have been observed in patients receiving secukinumab (see section 4.8). 
V kliničnih študijah so pri bolnikih, ki so prejemali sekukinumab, opažali pojavljanje okužb (glejte poglavje 4.8).
Psoriasis study 1 (ERASURE) evaluated 738 patients. 
V 1. študiji psoriaze (študiji ERASURE) so ocenjevali 738 bolnikov.
Do not open the sealed outer box until you are ready to use this medicine. 
Originalno zaprto zunanjo škatlo odprite šele takrat, ko boste pripravljeni za injiciranje zdravila.
Serious infections occurred in 0.14% of patients treated with secukinumab and in 0.3% of patients treated with placebo (see section 4.4). 
Do resnih okužb je prišlo pri 0,14 % bolnikov, ki so prejemali sekukinumab, in pri 0,3 % bolnikov, ki so prejemali placebo (glejte poglavje 4.4).
With the needle pointing upward, gently tap the syringe to move any air bubbles to the top. 
Konico igle usmerite navzgor in nežno potrkajte po brizgi, da se bodo morebitni zračni mehurčki premaknili proti vrhu.
Greater response rates favouring 300 mg were also observed for ASAS partial remission (ASAS PR) response at week 16 and were maintained up to week 156. 
Večje deleže bolnikov z odzivom v prid odmerku 300 mg so opažali tudi pri delni remisiji po kriterijih ASAS (ASAS partial remission, ASAS PR) do 16. tedna in to se je ohranilo do 156. tedna.
Over the entire treatment period (a total of 3,430 patients treated with secukinumab for up to 52 weeks for the majority of patients), infections were reported in 47.5% of patients treated with secukinumab (0.9 per patient-year of follow-up). 
V celotnem obdobju zdravljenja (ko je skupno 3.430 bolnikov prejemalo sekukinumab, večinoma do 52 tednov) so o okužbah poročali pri 47,5 % bolnikov, ki so prejemali sekukinumab (0,9 na enoto bolnik-leto spremljanja).
As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. 
Na ta način sekukinumab posredno zavira sproščanje provnetnih citokinov, kemokinov in mediatorjev, ki povzročajo poškodbe tkiva, in zmanjša delovanje ter vpletenost IL-17A pri avtoimunskih in vnetnih boleznih.
The mean elimination half-life, as estimated from population pharmacokinetic analysis, was 27 days in plaque psoriasis patients, ranging from 18 to 46 days across psoriasis studies with intravenous administration. 
Povprečni razpolovni čas izločanja je bil pri bolnikih s psoriazo s plaki po rezultatih analize populacijske farmakokinetike ocenjen na 27 dni in se je v študijah psoriaze z intravenskim odmerjanjem gibal v obsegu od 18 do 46 dni.
Table 5 Clinical response in PsA study 2 and PsA study 3 at week 16 and week 24 
Preglednica 5 Klinični odziv v PsA študiji 2 in PsA študiji 3 po 16 in 24 tednih
ASAS: Assessment of SpondyloArthritis International Society Criteria; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; hsCRP: high-sensitivity C-reactive protein; ASDAS: Ankylosing Spondylitis Disease Activity Score; BSL: baseline 
ASAS: ocena po kriterijih Mednarodnega združenja za spondiloartritis (ASAS - Assessment of Spondyloarthritis International Society); BASDAI: ocena Bathovega indeksa aktivnosti bolezni (BASDAI- Bath Ankylosing Spondylitis Disease Activity Index); hsCRP: C reaktivni protein visoke občutljivosti (hsCRP: C - high-sensitivity C-reactive protein); ASDAS: ocena aktivnosti ankilozirajočega spondilitisa (ASDAS - Ankylosing Spondylitis Disease Activity Score)
Keep the vial standing at room temperature for a minimum of 10 minutes to allow for dissolution. 
Vialo pustite stati na sobni temperaturi najmanj 10 minut, da se vsebina lahko raztopi.
Rare cases of neutropenia <0.5x10 
V redkih primerih so poročali o nevtropeniji z vrednostmi <0,5 x 10
After the medicine has been injected the syringe guard will be activated to cover the needle. 
Po injiciranju zdravila se zapiralo brizge aktivira in pokrije iglo.
For Psoriatic Arthritis study 1 (PsA study 1) and Psoriatic Arthritis study 2 (PsA study 2), the primary endpoint was at week 24. 
V 1. študiji psoriatičnega artritisa (PsA študiji 1) in v 2. študiji psoriatičnega artritisa (PsA študiji 2) so primarni cilj opazovali po 24 tednih.
1 pre-filled SensoReady pen 2 pre-filled SensoReady pens 
1 napolnjen injekcijski peresnik SensoReady 2 napolnjena injekcijska peresnika SensoReady
There was an increase in mucosal or cutaneous candidiasis, consistent with the mechanism of action, but the cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. 
Pogosteje je prihajalo do kandidoze sluznic in kože, kar je v skladu z mehanizmom delovanja zdravila, primeri pa so bili blago ali zmerno izraženi, niso bili opredeljeni kot resni, odzivali so se na običajno zdravljenje in zaradi njih ni bilo treba prekiniti zdravljenja psoriaze.
What Cosentyx looks like and contents of the pack Cosentyx powder for solution for injection is a white solid powder in a glass vial. 
Izgled zdravila Cosentyx in vsebina pakiranja Cosentyx prašek za raztopino za injiciranje je bel trden prašek v stekleni viali.
The European Medicines Agency has waived the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from birth to less than 6 years and in chronic idiopathic arthritis for paediatric patients aged from birth to less than 2 years (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Cosentyx pri psoriazi s plaki pri pediatričnih bolnikih v starostnem obdobju od rojstva do manj kot 6 let in pri kroničnem idiopatskem artritisu pri pediatričnih bolnikih v starostnem obdobju od rojstva do manj kot 2 leti (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Inhibition of progression of structural damage was also assessed in PsA study 1 at weeks 24 and 52, compared to baseline. 
Zaviranje napredovanja strukturnih okvar so ocenjevali tudi v PsA študiji 1 po 24 in po 52 tednih v primerjavi z izhodiščno vrednostjo.
Psoriasis study 5 (SCULPTURE) evaluated 966 patients. 
V 5. študiji psoriaze (študiji SCULPTURE) so ocenjevali 966 bolnikov.
The number of PsA patients with axial involvement was too small to allow meaningful assessment. 
Število bolnikov s psoriatičnim artritisom z aksialno prizadetostjo je bilo premajhno za ločeno ocenjevanje te podskupine.
In clinical studies, urticaria and rare cases of anaphylactic reaction to secukinumab were observed (see also section 4.4). 
V kliničnih študijah so opažali pojavljanje urtikarije in redke primere anafilaktične reakcije na sekukinumab (glejte tudi poglavje 4.4).
ADRs from clinical studies and post-marketing reports (Table 1) are listed by MedDRA system organ class. 
Neželeni učinki zdravila iz kliničnih študij ter poročil iz obdobja uporabe zdravila po prihodu na trg (preglednica 1) so navedeni po organskih sistemih klasifikacije MedDRA.
If necessary, Cosentyx may be stored unrefrigerated for a single period of up to 4 days at room temperature, not above 30°C. 
Če je potrebno, je zdravilo Cosentyx mogoče hraniti izven hladilnika v enkratnem največ 4-dnevnem obdobju pri sobni temperaturi, ki ne presega 30 °C.
Serious infections were reported in 1.2% of patients treated with secukinumab (0.015 per patient-year of follow-up). 
O resnih okužbah so poročali pri 1,2 % bolnikov, ki so prejemali sekukinumab (0,015 na enoto bolnik-leto spremljanja).
What you need for your injection: 
Kaj potrebujete pri injiciranju:
About half of the treatment-emergent anti-drug antibodies were neutralising, but this was not associated with loss of efficacy or pharmacokinetic abnormalities. 
Med protitelesi, ki so bila usmerjena proti zdravilu in so se razvila zaradi zdravljenja, je bilo približno pol nevtralizirajočih protiteles, vendar to ni zmanjšalo učinkovitosti zdravila ali povzročilo farmakokinetičnih nepravilnosti.
Prepare the required number of syringes (2 syringes for the 300 mg dose). 
Pripravite potrebno število brizg (2 brizgi za odmerek 300 mg).
Cosentyx is used to treat a skin condition called “plaque psoriasis”, which causes inflammation affecting the skin. 
Zdravilo Cosentyx uporabljamo za zdravljenje kožne bolezni, ki jo imenujemo "psoriaza s plaki" (psoriaza v obliki plošč), le-ta povzroča vnetje, ki prizadene kožo.
Table 2 Summary of PASI 50/75/90/100 & IGA mod 2011 “clear” or “almost clear” clinical response in psoriasis studies 1, 3 and 4 (ERASURE, FEATURE and JUNCTURE) 
Preglednica 2 Pregled kliničnih odzivov PASI 50/75/90/100 & IGA mod 2011 "brez znakov" oziroma "skoraj brez znakov"v 1., 3. in 4. študiji psoriaze (v študijah ERASURE, FEATURE in JUNCTURE)
Of the 2,403 patients who were included in the placebo-controlled studies, 79% were biologic-naive, 45% were non-biologic failures and 8% were biologic failures (6% were anti-TNF failures, and 2% were anti-p40 failures). 
Med 2.403 bolniki, ki so bili vključeni v s placebom kontrolirane študije, jih 79 % pred tem še ni prejemalo bioloških zdravil, pri 45 % je bilo neuspešno predhodno zdravljenje, ki ni vključevalo bioloških zdravil, pri 8 % pa je bilo neuspešno predhodno zdravljenje z biološkimi zdravili (pri 6 % z zaviralci TNF in pri 2 % z zdravili proti podenoti p40).
The most frequently reported adverse drug reactions (ADRs) are upper respiratory tract infections (most frequently nasopharyngitis, rhinitis). 
Najbolj pogosti neželeni učinki, o katerih so poročali, so okužbe zgornjih dihal (najpogosteje so poročali o nazofaringitisu in rinitisu).
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. 
Zdravilo Cosentyx je indicirano za zdravljenje aktivnega ankilozirajočega spondilitisa pri odraslih z nezadostnim odzivom na konvencionalno terapijo.
ASAS 20 response, % 
odziv ASAS 20, %
Detailed instructions for use are provided in the package leaflet. 
Podrobna navodila za uporabo zdravila lahko najdete v priloženem Navodilu za uporabo.
Secukinumab 300 mg was superior to placebo at week 12 as assessed by significant improvement from baseline in both the PSSI 90 response (52.9% versus 2.0%) and IGA mod 2011 0 or 1 scalp only response (56.9% versus 5.9%). 
Sekukinumab 300 mg je bil po 12 tednih boljši od placeba, kar se je pokazalo s pomembnim izboljšanjem od izhodišča tako odziva PSSI 90 (52,9 % v primerjavi z 2,0 %) kot odziva z oceno IGA mod 2011 0 ali 1 (56,9 % v primerjavi s 5,9 %).
In PsA study 1 and PsA study 2, efficacy was maintained up to week 104. 
V PsA študiji 1 in 2 se je učinkovitost zdravila ohranjala do konca 104. tedna.
Based on clinical response, the dose can be increased to 300 mg. 
Na osnovi kliničnega odziva je mogoče odmerek zvišati na 300 mg.
The needle cap of the syringe may contain dry rubber (latex), which should not be handled by persons sensitive to this substance. 
Pokrovček igle pri tej brizgi lahko vsebuje suho gumo (lateks), zato osebe, ki so preobčutljive na lateks, ne smejo rokovati z navedenim pokrovčkom.
Withdraw slightly more than 1.0 ml sterile water for injections into a 1 ml graduated disposable syringe and adjust to 1.0 ml. 
V umerjeno 1-mililitrsko brizgo za enkratno uporabo potegnite nekoliko več kot 1,0 ml sterilne vode za injekcije, nato pa volumen uravnajte na 1,0 ml.
In a study, after meningococcal and inactivated influenza vaccinations, a similar proportion of healthy volunteers treated with 150 mg of secukinumab and those treated with placebo were able to mount an adequate immune response of at least a 4-fold increase in antibody titres to meningococcal and influenza vaccines. 
V študiji so zdravi prostovoljci, ki so prejeli 150 mg sekukinumaba, in tisti, ki so prejeli placebo, po prejemu meningokoknega cepiva in inaktiviranega cepiva proti gripi v približno enakem deležu razvili ustrezen imunski odziv z najmanj 4-kratnim porastom titrov protiteles proti meningokoknemu cepivu in cepivu proti gripi.
Anti-tuberculosis therapy should be considered prior to initiation of secukinumab in patients with latent tuberculosis. 
Pri bolnikih z latentno tuberkulozo je treba pred začetkom uporabe sekukinumaba razmisliti o zdravljenju s tuberkulostatiki.
• The recommended dose is 300 mg by subcutaneous injection. 
• Priporočeni odmerek je 300 mg s subkutano injekcijo.
This needle will only be used for withdrawing Cosentyx into the disposable syringe. 
To iglo boste uporabili samo za to, da boste zdravilo Cosentyx potegnili v brizgo za enkratno uporabo.
For Psoriatic Arthritis study 3 (PsA study 3), the primary endpoint was at week 16 with the key secondary endpoint, the change from baseline in modified Total Sharp Score (mTSS), at week 24. 
V 3. študiji psoriatičnega artritisa (PsA študiji 3) so primarni cilj opazovali po 16 tednih, ključni sekundarni cilj, to je spremembo modificirane skupne Sharpove ocene (mTSS - modified total Sharp Score) od izhodišča, pa po 24 tednih.
Note that foaming of the solution may occur. 
Upoštevajte, da se raztopina pri tem lahko peni.
Insert the syringe needle into the vial containing the powder through the centre of the rubber stopper and reconstitute the powder by slowly injecting 1.0 ml of sterile water for injections into the vial. 
Iglo brizge skozi sredino gumijaste zaporke vstavite v vialo, v kateri je prašek, in s počasnim injiciranjem 1,0 ml sterilne vode za injekcije v vialo rekonstituirajte prašek.
The European Medicines Agency has deferred the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from 6 years to less than 18 years and in chronic idiopathic arthritis for paediatric patients aged from 2 years to less than 18 years (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Cosentyx pri psoriazi s plaki pri pediatričnih bolnikih v starostnem obdobju od 6 do manj kot 18 let in pri kroničnem idiopatskem artritisu pri pediatričnih bolnikih v starostnem obdobju od 2 do manj kot 18 let (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
• signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections (neutropenia) 
• znaki znižanega števila levkocitov, kot so zvišana telesna temperatura, vneto grlo oziroma žrelo ali razjede v ustih zaradi okužbe (nevtropenija),
Cosentyx is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen with transparent window and label. 
Zdravilo Cosentyx je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo, ki je vgrajena v peresnik trirobne oblike s prozornim okencem in nalepko.
Population pharmacokinetic analysis showed that secukinumab was absorbed with an average absolute bioavailability of 73% in patients with plaque psoriasis. 
Rezultati analize populacijske farmakokinetike so pokazali, da se pri bolnikih s psoriazo s plaki sekukinumab absorbira s povprečno absolutno biološko uporabnostjo 73 %.
The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis. 
Večina protiteles IgG se izloča s pomočjo znotrajceličnega katabolizma po predhodnih procesih pinocitoze in receptorske endocitoze.
Be careful not to touch the syringe guard wings before use. 
Pazite, da se pred odmerjanjem ne boste dotikali zapirala brizge.
How to use Cosentyx 
Kako uporabljati zdravilo Cosentyx